MX2011010908A - Anticuerpos anti-tnf-alfa y sus usos. - Google Patents

Anticuerpos anti-tnf-alfa y sus usos.

Info

Publication number
MX2011010908A
MX2011010908A MX2011010908A MX2011010908A MX2011010908A MX 2011010908 A MX2011010908 A MX 2011010908A MX 2011010908 A MX2011010908 A MX 2011010908A MX 2011010908 A MX2011010908 A MX 2011010908A MX 2011010908 A MX2011010908 A MX 2011010908A
Authority
MX
Mexico
Prior art keywords
tnf
antibodies
overproduction
activity
present disclosure
Prior art date
Application number
MX2011010908A
Other languages
English (en)
Inventor
David B Powers
Fiona A Harding
Yoshiko Akamatsu
Robert B Dubridge
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Publication of MX2011010908A publication Critical patent/MX2011010908A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a anticuerpos dirigidos al factor de necrosis tumoral ("TNF-a") y usos de dichos anticuerpos, por ejemplo, para tratar enfermedades asociadas con la actividad y/o sobre-producción de TNF-a.
MX2011010908A 2009-04-16 2010-04-16 Anticuerpos anti-tnf-alfa y sus usos. MX2011010908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17005309P 2009-04-16 2009-04-16
PCT/US2010/031406 WO2010121140A1 (en) 2009-04-16 2010-04-16 ANTI-TNF-α ANTIBODIES AND THEIR USES

Publications (1)

Publication Number Publication Date
MX2011010908A true MX2011010908A (es) 2012-02-21

Family

ID=42470707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010908A MX2011010908A (es) 2009-04-16 2010-04-16 Anticuerpos anti-tnf-alfa y sus usos.

Country Status (23)

Country Link
US (3) US8722860B2 (es)
EP (2) EP2419448A1 (es)
JP (1) JP5795759B2 (es)
KR (1) KR20110138412A (es)
CN (1) CN102439040B (es)
AU (1) AU2010236256C1 (es)
BR (1) BRPI1012524A2 (es)
CA (1) CA2758964A1 (es)
CL (1) CL2011002567A1 (es)
CO (1) CO6450656A2 (es)
CR (1) CR20110526A (es)
DO (1) DOP2011000316A (es)
EC (1) ECSP11011450A (es)
GT (1) GT201100260A (es)
IL (1) IL215649A (es)
MX (1) MX2011010908A (es)
NZ (1) NZ595687A (es)
PE (1) PE20120835A1 (es)
RU (1) RU2595379C2 (es)
SG (1) SG175181A1 (es)
TW (1) TWI559930B (es)
WO (1) WO2010121140A1 (es)
ZA (1) ZA201107486B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010908A (es) 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anticuerpos anti-tnf-alfa y sus usos.
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
CN102998457B (zh) * 2012-07-12 2015-08-26 电子科技大学 草鱼肿瘤坏死因子alpha的竞争抑制酶联免疫检测方法
LT2897978T (lt) * 2012-09-19 2017-06-12 Abbvie Biotherapeutics Inc. Antikūnų su sumažintu imunogeniškumu identifikavimo būdas
US20150368333A1 (en) * 2013-01-24 2015-12-24 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
BR112015022119A2 (pt) 2013-03-15 2017-08-29 Abbvie Biotherapeutics Inc Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
CN104341502B (zh) * 2013-08-09 2016-04-27 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α全人源单抗及其应用
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP6832707B2 (ja) * 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー ＴＮＦαに対する結合メンバー
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
KR20170084328A (ko) * 2014-11-21 2017-07-19 엘리 디. 에렌프라이스 모노클로날 항체의 투여를 위한 병용 요법
WO2016130451A1 (en) * 2015-02-09 2016-08-18 Dnx Biotech, Llc Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
WO2016149139A1 (en) * 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN107849150B (zh) 2015-06-24 2021-12-14 Jcr制药股份有限公司 含有bdnf的融合蛋白
AU2016283343B2 (en) 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
AU2016302539A1 (en) 2015-07-31 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Antibody variants
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
PE20190416A1 (es) 2016-06-14 2019-03-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
IL276191B2 (en) 2016-12-26 2024-02-01 Japan Chem Res A new anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier
JOP20190162A1 (ar) * 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
AU2019211910B2 (en) 2018-01-25 2022-09-22 Fujimoto Co., Ltd Thiophene derivative and use thereof
EP3769089A4 (en) * 2018-03-19 2022-08-03 BioVentures, LLC PERIOSTIN ANTIBODIES AND METHODS OF USE THEREOF
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CN111909267B (zh) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用
CA3143478A1 (en) * 2019-07-09 2021-01-14 Tomer Hertz Antibodies with reduced immunogenicity
FR3104582A1 (fr) 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992006553A1 (en) 1990-10-02 1992-04-16 Lasermaster Corporation Line rasterization technique for a non-gray scale anti-aliasing method for laser printers
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1300173C (zh) * 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK0942968T3 (da) 1996-12-03 2008-06-23 Amgen Fremont Inc Fuldt humane antistoffer, der binder EGFR
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US7365166B2 (en) * 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
AU742045B2 (en) 1997-04-14 2001-12-13 Amgen Research (Munich) Gmbh Novel method for the production of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CN1279055C (zh) * 2000-06-16 2006-10-11 人体基因组科学有限公司 免疫特异性结合BLyS的抗体
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP1573002A4 (en) 2002-02-11 2008-07-16 Genentech Inc ANTIBODY VARIANTS WITH ACCELERATED ANTIGEN ASSOCIATED SPEEDS
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US9028816B2 (en) * 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
CN1938046B (zh) 2003-11-06 2014-03-19 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005049652A2 (en) 2003-11-17 2005-06-02 The Rothberg Institute For Childhood Diseases Methods of generating antibody diversity in vitro
JP2008507257A (ja) * 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Ｖ遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0511448A (pt) * 2004-07-06 2007-12-26 Bioren Inc anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
WO2006043972A1 (en) 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
KR101385886B1 (ko) * 2005-02-03 2014-04-24 안티토페 리미티드 인간 항체들과 단백질들
NZ595225A (en) * 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
AU2006251647A1 (en) * 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
AU2006261357A1 (en) * 2005-06-17 2006-12-28 Zimmer Spine Austin, Inc. Improved method of treating degenerative spinal disorders
TW200745332A (en) * 2005-07-21 2007-12-16 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ608431A (en) * 2005-11-01 2014-11-28 Abbvie Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
JP2009515516A (ja) 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
EP1987064A4 (en) * 2006-02-01 2010-04-07 Arana Therapeutics Ltd DOMAIN ANTIBODY CONSTRUCT
NZ610566A (en) * 2006-04-05 2014-09-26 Abbvie Biotechnology Ltd Antibody purification
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
CA2564435A1 (en) * 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
JP5570998B2 (ja) * 2007-12-31 2014-08-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＴＮＦαに対する抗体
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
MX2011010908A (es) 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anticuerpos anti-tnf-alfa y sus usos.

Also Published As

Publication number Publication date
US8722860B2 (en) 2014-05-13
JP5795759B2 (ja) 2015-10-14
TW201041592A (en) 2010-12-01
NZ595687A (en) 2013-11-29
IL215649A0 (en) 2012-01-31
AU2010236256B2 (en) 2015-05-28
JP2012524071A (ja) 2012-10-11
AU2010236256C1 (en) 2015-10-22
CA2758964A1 (en) 2010-10-21
DOP2011000316A (es) 2012-02-29
US9315573B2 (en) 2016-04-19
WO2010121140A1 (en) 2010-10-21
CO6450656A2 (es) 2012-05-31
US20120135005A1 (en) 2012-05-31
RU2011145428A (ru) 2013-05-27
CN102439040B (zh) 2017-05-03
KR20110138412A (ko) 2011-12-27
GT201100260A (es) 2013-01-24
AU2010236256A1 (en) 2011-11-03
ZA201107486B (en) 2012-06-27
SG175181A1 (en) 2011-11-28
EP2419448A1 (en) 2012-02-22
RU2595379C2 (ru) 2016-08-27
CN102439040A (zh) 2012-05-02
PE20120835A1 (es) 2012-07-23
IL215649A (en) 2016-03-31
US20100266613A1 (en) 2010-10-21
EP2918602A1 (en) 2015-09-16
CR20110526A (es) 2012-02-09
ECSP11011450A (es) 2012-03-30
TWI559930B (en) 2016-12-01
CL2011002567A1 (es) 2012-02-24
US20140212424A1 (en) 2014-07-31
BRPI1012524A2 (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
IN2012DN02081A (es)
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
JO2576B1 (en) Antibodies
WO2011143318A3 (en) Anti-fgfr2 antibodies
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2011113019A3 (en) Ctla4 proteins and their uses
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
AU2016219704A1 (en) Anti-Notch1 antibodies
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
UA105405C2 (ru) Гуманизированное антитело против человеческого il-22ra
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
SG178881A1 (en) Antibodies against cdcp1 for the treatment of cancer
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: PABEN PROYECTOS ESTRATEGICOS, S.A. DE C.V.

FG Grant or registration